Patent Reform

Danny Levine of the Burrill Report conducted a podcast with BIO President & CEO Jim Greenwood today on BIO's public priorities for 2010.

Economists have long recognized that the development and spread of economic innovations are the most powerful factors affecting how fast the U.S. economy grows and how much the incomes of most Americans will rise.

Certain groups are calling for serious overhaul of the nation‟s patent system.

On July 23rd, the House passed by voice vote an amendment on human patenting offered by Dave Weldon (R-Fla.) as part of the Commerce-Justice-State appropriations bill (H.R. 2799).

In the early weeks of the 108th Congress, two Senate bills, S. 54 and S. 7, were introduced that embrace the "Greater Access to Affordable Pharmaceuticals Act of 2003" (GAAP), formerly known in the 107th Congress as S. 812

On October 24th the FDA published proposed regulations that affect implementation of the Hatch-Waxman law. These changes in part respond to recommendations in a July 2002 Federal Trade Commission (FTC) report and a Citizen Petition filed with the FDA by the FTC in May 2001.

Last week, the Senate Health, Education, Labor and Pensions (HELP) Committee marked-up legislation - The Edwards/Collins substitute to S. 812 - The "Greater Access to Affordable Pharmaceuticals Act of 2001" - that raises serious concerns for members of the Biotechnology Industry Organization (BIO).

Letters, Testimony & Comments

March 21 2013
BIO commends the Government of Peru for its endeavor to create a pathway for the approval of biological and biotechnological products....
February 22 2013
BIO commends the government of Colombia for taking steps towards developing regulatory requirements for the registry of medicines of...
February 1 2013
BIO commends the INPI for their efforts to devise guidelines for examining biotechnology related inventions. Given the technological...
February 1 2013
BIO respectfully submits both questions and comments for the National Health Surveillance Agency’s (ANVISA) consideration on the...
March 26 2012
From BIO’s perspective, Supplemental Examination may have significant benefits, because patents that undergo this process are...

Press Releases

May 14 2013
Washington, D.C. (May 13, 2013) Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO)...
September 8 2011
Washington, D.C. (September 8, 2011) – Biotechnology Industry Organization (BIO) President and CEO Jim...
June 23 2011
WASHINGTON, D.C. (Thursday, June 23, 2011) - Biotechnology Industry Organization (BIO) President and CEO Jim...
June 21 2011
WASHINGTON, D.C. (Tuesday, June 21, 2011) - Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood...
May 3 2011
WASHINGTON, D.C. (Tuesday, May 03, 2011) - The Biotechnology Industry Organization (BIO) announced today its...